Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas

Cancer

Volumn 104, Issue 10, 2005, Pages 2266-2274

  Keller, Gunhild ^a,b   Schally, Andrew V ^a,b   Nagy, Attila ^a,b   Halmos, Gabor ^a,b   Baker, Benjamin ^a,b   Engel, Jorg B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bombesin gastrin releasing peptide receptor; Cytotoxic bombesin analogue AN 215; MDR 1; Multidrug resistance associated protein subtype 1; Multiple drug resistance; Renal cell carcinoma; Targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 210; AN 215; BOMBESIN DERIVATIVE; DOXORUBICIN DERIVATIVE; GASTRIN RELEASING PEPTIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RC 3094; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; KIDNEY CARCINOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSPLANTATION; CHEMOKINES, CC; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; PYRROLES; RECEPTORS, BOMBESIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 27644545827     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21402     Document Type: Article

References (43)

1. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002;29:41-46.
2. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol. 2003;45:177-190.
3. Moscow J, Morrow CS, Cawan KH. Drug resistance and clinical circumvention. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Cancer medicine, 6th ed, chapter 48. Hamilton: BC Dekker Publishers, 2004:711-725.
4. Strohmaier WL. New treatment modalities-the urologist's view. Anticancer Res. 1999;19:1605-1609.
5. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4:385-390.
6. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177-186.
7. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res. 1999;19:1541-1543.
8. Nishiyama K, Shirahama T, Yoshimura A, et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer. 1993;71:3611-3619.
9. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantification of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest. 1995;95:2205-2214.
10. Duensing S, Dallmann I, Grosse J, et al. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology. 1994;51:309-313.
11. Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol. 1996;156:506-511.
12. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004;15:300-310.
13. Schally AV, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 2001; 22:248-291.
14. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985;316:823-826.
15. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer. 1989;63:1714-1720.
16. Wang QJ, Knezetic JA, Schally AV, Pour PM, Adrian TE. Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer. 1996;68:528-534.
17. Yano T, Pinski J, Groot K, Schally AV. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992;52:4545-4547.
18. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8:1139-1146.
19. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin releasing pepetide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55:280-287.
20. Sun B, Halmos G, Schally AV, WangX, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295-303.
21. Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004;61:1042-1068.
22. Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA. 1997;94:652-656.
23. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer. 2000;88:652-657.
24. Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. Br J Cancer. 1999;81:966-971.
25. Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer. 2003;98:1401-1410.
26. Szereday Z, Schally AV, Nagy A, et al. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer. 2002;86:1322-1327.
27. Pansky A, De Weerth A, Fasler-Kan E, et al. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J Am Soc Nephrol. 2000;11:1409-1418.
28. Radulovic S, Cai RZ, Serfozo P, et al. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP RECEPTOR ANTAGONISTs with N-terminal D-Trp or D-Tpi. Int J Peptide Protein Res. 1991;38:593-600.
29. Jungwirth A, Schally AV, Halmos G, et al. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer. 1998;82:909-917.
30. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA. 1997;94:956-960.
31. Rasmussen. Quantification on the LightCycler. In: Meuer S, Wittwer CT, Nakagawara K, editors. Rapid cycle real-time PCR, methods and applications. Heidelberg: Springer Press, 2001:21-34.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
33. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
34. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177-186.
35. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12:450-458.
36. Moscow J, Morrow CS, Cowan KH. Drug resistance and its clinical circumvention. In: Holland F, editor. Cancer medicine, 6th ed, vol 1. London: Hamilton, 2003:711-725.
37. Chapman AE, Goldstein LJ. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol. 1995;22:17-28.
38. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res. 1990; 50:3670-3674.
39. Volm M, Pommerenke EW, Efferth T, Lohrke H, Mattern J. Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro. Cancer. 1991;67:2484-2489.
40. Efferth T, Dunn TA, Berlion M, Langenbahn H, Pommerenke EW, Volm M. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788. Anticancer Res. 1993;13:905-908.
41. Murphy BR, Rynard SM, Pennington K, Grosh W, Loehrer PJ. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma: a Hoosier Oncology Group study. Am J Clin Oncol. 1994;17:10-13.
42. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res. 1997;3:2005-2015.
43. Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of pre-clinical studies. Proc Natl Acad Sci USA. 2000;97:829-834.